ADVENTRX Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, an emulsion formulation of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, as well as to treat advanced or metastatic breast cancer; and ANX-514, an emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. The company was founded in 1995 is headquartered in San Diego, California
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.